Replies to post #182923 on Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

Brilacidin is easier to value since there are studies that compared it with drugs currently on the market. But, there are also 2 B versions where there is no effective treatment, only market estimates. If B is great, highly effective against UP and OM, plus what we know of ABSSSI, those 3 alone would be expected to generate annual sales of about $1 billion each by the 3rd year on the market. Using a very conservative 3 times potential sales as a benchmark, the cap can be expected to settle in above $9 billion. 180 million shares fully diluted works out to about $50 a share, just for Brilacidin and its 3 lead indications.

[cybermich]

Kahuna gave a pretty good answer..

but just to add.. CTIX has so many end games because of all of B's indications.

And what about P?.. if proven to be as effective as Biologics then the value of P alone could also fetch a similar valuation (as mentioned.)

IF K turns out to effectively activate P53.. it could potentially be an effective treatment in those cancers where P53 is is compromised (up to 80 percent of all cancer)..

imagine if K is some day used as often as chemo (but without the nasty side effects).. even if not a stand alone treatment?..

so there again.. K alone being "great" could make 1.60 seem like the deal of a lifetime:)

So answer:

All we kneed is one (K, B OR P) to be great.. and the gains could be life changing depending on the number of shares you have...

but even if just one of those are "good".. this will be a "great" investment.

Good luck to all CTIX investors.